ARCT

16.27

1.56% 0.25

Handel nachbörslich: 16.95 0.68 +4.18%

Arcturus Therapeutics Holdings Inc (ARCT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$16.02

Offen:

$16.08

24-Stunden-Volumen:

939.60K

Relative Volume:

2.56

Marktkapitalisierung:

$460.36M

Einnahmen:

$157.75M

Nettoeinkommen (Verlust:

$-29.73M

KGV:

5.4415

EPS:

2.99

Netto-Cashflow:

$-21.00M

1W Leistung:

-20.13%

1M Leistung:

-23.07%

6M Leistung:

-45.37%

1J Leistung:

-34.89%

1-Tages-Spanne:

$15.71

$17.37

1-Wochen-Bereich:

$14.93

$20.07

52-Wochen-Spanne:

$14.93

$45.00

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

Firmenname

Arcturus Therapeutics Holdings Inc

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

(858) 900-2660

Adresse

10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA

Mitarbeiter

180

Twitter

@ArcturusRx

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

ARCT's Discussions on Twitter

Vergleichen Sie ARCT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ARCT	16.27	460.36M	157.75M	-29.73M	-21.00M	2.99
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-07-24	Eingeleitet	William Blair	Outperform
2023-05-11	Hochstufung	H.C. Wainwright	Neutral → Buy
2022-11-14	Fortgesetzt	Wells Fargo	Overweight
2022-11-10	Herabstufung	Robert W. Baird	Neutral → Underperform
2022-11-03	Hochstufung	Citigroup	Neutral → Buy
2022-11-02	Hochstufung	Barclays	Underweight → Equal Weight
2022-08-10	Herabstufung	Raymond James	Mkt Perform → Underperform
2022-07-19	Fortgesetzt	Cantor Fitzgerald	Overweight
2022-05-11	Hochstufung	Robert W. Baird	Underperform → Neutral
2022-04-21	Herabstufung	Citigroup	Buy → Neutral
2022-01-31	Hochstufung	Raymond James	Underperform → Mkt Perform
2021-08-12	Herabstufung	Raymond James	Mkt Perform → Underperform
2021-08-11	Herabstufung	Goldman	Neutral → Sell
2021-08-10	Herabstufung	Robert W. Baird	Neutral → Underperform
2021-07-02	Eingeleitet	Cantor Fitzgerald	Overweight
2021-06-25	Fortgesetzt	Goldman	Neutral
2021-06-21	Herabstufung	Barclays	Equal Weight → Underweight
2021-06-04	Fortgesetzt	Robert W. Baird	Neutral
2021-02-17	Herabstufung	B. Riley Securities	Neutral → Sell
2021-01-19	Herabstufung	B. Riley Securities	Buy → Neutral
2021-01-15	Herabstufung	B. Riley Securities	Buy → Neutral
2021-01-07	Eingeleitet	Wells Fargo	Overweight
2020-12-29	Herabstufung	Barclays	Overweight → Equal Weight
2020-12-29	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-12-29	Herabstufung	Raymond James	Outperform → Mkt Perform
2020-12-29	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-12-23	Herabstufung	ROTH Capital	Buy → Sell
2020-12-08	Bestätigt	B. Riley Securities	Buy
2020-12-07	Bestätigt	B. Riley Securities	Buy
2020-10-26	Eingeleitet	Barclays	Overweight
2020-10-06	Eingeleitet	Citigroup	Buy
2020-08-26	Eingeleitet	Piper Sandler	Overweight
2020-07-30	Fortgesetzt	ROTH Capital	Buy
2020-07-16	Eingeleitet	Raymond James	Outperform
2020-07-13	Eingeleitet	B. Riley FBR	Buy
2020-06-09	Herabstufung	WBB Securities	Buy → Hold
2020-02-11	Eingeleitet	Robert W. Baird	Outperform
2020-02-07	Eingeleitet	Guggenheim	Buy
2020-02-06	Eingeleitet	Guggenheim	Buy
2019-04-05	Eingeleitet	H.C. Wainwright	Buy
2018-09-20	Hochstufung	WBB Securities	Buy → Strong Buy
2018-01-22	Eingeleitet	Chardan Capital Markets	Buy

Alle ansehen

Arcturus Therapeutics Holdings Inc Aktie (ARCT) Neueste Nachrichten

08:04 AM

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference - StockTitan

08:04 AM

Nov 16, 2024

Sumitomo Mitsui Trust Group Inc. Buys 712,650 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat

Nov 16, 2024

Nov 15, 2024

Avian Flu: FDA Authorizes Self-Replicating Vaccine Trial to Bill Gates-Backed Company, "Study Can Proceed" - presskit.it

Nov 15, 2024

Nov 14, 2024

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data (NASDAQ:ARCT) - Seeking Alpha

Nov 14, 2024

Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production | ARCT Stock News - StockTitan

Nov 14, 2024

Nov 12, 2024

Arcturus gains IND clearance for H5N1 influenza sa-RNA vaccine candidate - BioWorld Online

Nov 12, 2024

Possible Signal As Arcturus Therapeutics Holdings Insiders Sell US$1.6m In Stock - Simply Wall St

Nov 12, 2024

Another Avian Influenza mRNA Vaccine Candidate Advances - Precision Vaccinations

Nov 12, 2024

Nov 11, 2024

Arcturus Gets FDA Green Light for H5N1 Flu mRNA Vaccine Trial, Backed by BARDA | ARCT Stock News - StockTitan

Nov 11, 2024

What is HC Wainwright's Estimate for ARCT FY2028 Earnings? - MarketBeat

Nov 11, 2024

Arcturus Therapeutics’ (ARCT) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 11, 2024

Nov 09, 2024

Earnings call: Arcturus Therapeutics reported a net loss of $6.9 million - Investing.com Australia

Nov 09, 2024

Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 09, 2024

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Nov 08, 2024

Nikko Asset Management Americas, Inc. Expands Stake in Arcturus Therapeutics Holdings Inc. - GuruFocus.com

Nov 08, 2024

Arcturus Therapeutics (NASDAQ:ARCT) Receives "Buy" Rating from HC Wainwright - MarketBeat

Nov 08, 2024

ARK Investment Management LLC Has $48.77 Million Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat

Nov 08, 2024

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Average Target Price from Brokerages - Defense World

Nov 08, 2024